Table 3.
Clinical properties | Total | HPV status (n/%) | ||
---|---|---|---|---|
Negative (%) | Positive (%) | P value | ||
Gender | ||||
Male | 78 | 42(62.7 %) | 36(64.3 %) | 0.855 |
Female | 45 | 25(37.3 %) | 20(35.7 %) | |
Age (mean) | ||||
<57 | 55 | 29(43.9 %) | 26(47.3 %) | 0.714 |
≥57 | 66 | 37(56.1 %) | 29(52.7 %) | |
Histopathological gradea | ||||
Well | 28 | 15(22.4 %) | 13(23.6 %) | 0.937 |
Moderate | 77 | 42(62.7 %) | 35(63.6 %) | |
Poor | 17 | 10(14.9) | 7(12.7 %) | |
Invasion depth | ||||
T1-T2 | 59 | 37(55.2 %) | 22(40.0 %) | 0.094 |
T3-T4 | 63 | 30(44.8 %) | 33(60.0 %) | |
Lymphatic invasion | ||||
N0 | 55 | 28(43.8 %) | 27(50.9 %) | 0.438 |
N1-N3 | 62 | 36(56.2 %) | 26(49.1 %) | |
TNM Staging | ||||
I/II | 74 | 40(61.5 %) | 34(65.4 %) | 0.668 |
III/IV | 43 | 25(38.5 %) | 18(34.6 %) |
a Well differentiation vs. moderate + poor differentiation